DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Cohance Lifesciences Limited (COHANCE) share price today?

Cohance Lifesciences Limited (COHANCE) is trading at ₹462.35 on the NSE, up 0.52% on the day. Source: DocStoX.

What is the PE ratio of Cohance Lifesciences Limited?

Cohance Lifesciences Limited has a price-to-earnings (PE) ratio of 98.6 in the Healthcare sector.

What is the market capitalisation of Cohance Lifesciences Limited?

Cohance Lifesciences Limited has a market capitalisation of approximately ₹17,751 crore.

Is Cohance Lifesciences Limited a profitable company?

Cohance Lifesciences Limited generates a return on equity of 4.6% with a net profit margin of 6.6%. That is a modest return on shareholder capital.

What is the 52-week high and low of COHANCE?

Cohance Lifesciences Limited (COHANCE) has traded between ₹266.7 and ₹917.85 over the past 52 weeks, against a current price of ₹462.35.

Does Cohance Lifesciences Limited pay a dividend?

Yes. Cohance Lifesciences Limited currently offers a dividend yield of 1.35%. Dividend payments depend on the board's declaration each year.

Cohance Lifesciences Limited

₹462.35▲ +2.40 (+0.52%)

COHANCE·NSE·Healthcare

Market Cap

17750.60 Cr

PE Ratio

98.58

Volume

6,98,502

Day High - Low

467.35 - 458.10

52W High-Low

917.85 - 266.70

₹462.35▲ +2.40 (+0.52%)

Market Cap17750.60 Cr

PE Ratio98.58

Volume6,98,502

Day High - Low467.35 - 458.10

52W High-Low917.85 - 266.70

Cohance Lifesciences Limited (COHANCE): company summary

The company's annual revenue fell 13.0% year-over-year, while net profit dropped 69.0%.

Cohance Lifesciences Limited (COHANCE) is a small-cap Healthcare company valued at ₹17,751 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move: Cohance Lifesciences Limited last traded at ₹462.35, modestly up 0.52% on the day.
Recent developments: On 2026-06-30, the company reported a net profit loss of ₹45 crore for the latest quarter, reversing a net profit of ₹46 crore in the same quarter a year earlier. Promoter shares pledged increased to 94.56% of promoter holding as of 2026-06-30.
Financial performance: The company's annual revenue fell 13.0% year-over-year, while net profit dropped 69.0%. The latest quarter saw revenue decline 23.1% compared to the same quarter a year earlier, and net profit swung from a profit of ₹46 crore to a loss of ₹45 crore.
Valuation multiples: The stock trades at 98.6 times earnings, a premium to the Healthcare median of 32.0, 4.36 times book value. It yields 1.4%.
Things to watch: The company's net profit margin narrowed 11.9 percentage points to 6.6%. The latest quarter ended with a net profit loss of ₹45 crore, reversing a net profit of ₹46 crore in the same quarter a year earlier. The stock is 50.8% below its 52-week high.
Where it stands: The company's business is declining, with annual net profit falling 69.0% and the latest quarter ending in a net loss. The stock is 50.8% below its 52-week high, and promoter shares pledged now account for 94.56% of promoter holding.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

DocStoX Score

3.6/10

Poor

Fair Value

ROE

4.58%

Weak

P/E

98.58x

Expensive

Debt / Equity

0.10

Low

Industry

Healthcare

Pharmaceuticals

Overall View

Mixed

Price performance

NIFTY 500NIFTY SMALLCAP 250

Day₹458.10

₹467.35

52W₹266.70

₹917.85

DocStoX take

Supported by risk (8.3), but held back by valuation (0.0). Risk looks strong at 8.3, but that is offset by valuation at 0.0 and momentum at 2.1 and growth at 2.8. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence

3.6

/10

Poor

Quality

Modest

ROE 4.6%

Valuation

Expensive

P/E 98.6×

Growth

Flat

Revenue +17.6% 5Y CAGR

Risk

Low risk

D/E 0.10

Momentum

Weak

30% of 52-week range

DocStoX research

Our verdict

Fairly Valued

Fair value not available

Current price

₹462

Upside / Downside

—

Implied CAGR

—

Priced in by the market

Uncertainty

—

Est. confidence

At a glance

Market Cap

₹17,751 Cr

52W High / Low

₹918 / ₹267

Dividend Yield

1.35%

Promoter Holding

57.48%

EPS (TTM)

₹4.69

Book Value

₹102.23

Key highlights

Low leverage — D/E 0.10
Profitable in all of the last 5 years
Revenue compounding 18% a year
Profit shrinking 16% a year
95% of promoter holding is pledged

3 Positives4 Watchouts

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Explore Cohance Lifesciences Limited’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.

Cohance Lifesciences Limited peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

Sun Pharmaceutical Industries Limited Divi's Laboratories Limited Torrent Pharmaceuticals Limited Apollo Hospitals Enterprise Limited Zydus Lifesciences Limited Laurus Labs Limited Cipla Limited Dr. Reddy's Laboratories Limited Aurobindo Pharma Limited Mankind Pharma Limited Lupin Limited Manipal Health Enterprises Limited

Compare Cohance Lifesciences Limited with peers

Cohance Lifesciences Limited vs Sun Pharmaceutical Industries Limited Cohance Lifesciences Limited vs Divi's Laboratories Limited Cohance Lifesciences Limited vs Torrent Pharmaceuticals Limited Cohance Lifesciences Limited vs Apollo Hospitals Enterprise Limited Cohance Lifesciences Limited vs Zydus Lifesciences Limited Cohance Lifesciences Limited vs Laurus Labs Limited

Related tools & concepts

Value Cohance Lifesciences Limited with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Explore further

COHANCE newsLatest coverage & filings Open screenerFilter the whole market